CEAC (oral semustine, etoposide, cytarabine and cyclophosphamide) vs BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimen of autologous stem cell transplantation for diffuse large B-cell lymphoma: a post-hoc, propensity score-matched, cohort study in Chinese patients
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CEAC (oral semustine, etoposide, cytarabine and cyclophosphamide) vs BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimen of autologous stem cell transplantation for diffuse large B-cell lymphoma: a post-hoc, propensity score-matched, cohort study in Chinese patients
Authors
Keywords
-
Journal
ANNALS OF HEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-11-07
DOI
10.1007/s00277-023-05513-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma
- (2023) Meng Lin et al. LEUKEMIA & LYMPHOMA
- Comparative Efficacy and Safety of Beam and Team Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoma Patients
- (2023) Burak Deveci et al. TRANSPLANTATION PROCEEDINGS
- Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study
- (2022) Domitille Costes-Tertrais et al. BONE MARROW TRANSPLANTATION
- Busulfan, Melphalan, and Etoposide (Bume) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High Risk Non-Hodgkin’s Lymphoma: A Multicenter Randomized Phase II Study by the Consortium for Improving Survival of Lymphoma (CISL)
- (2022) Kyoung Ha Kim et al. Cancer Research and Treatment
- Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
- (2022) Manali Kamdar et al. LANCET
- Diffuse Large B-Cell Lymphoma
- (2021) Laurie H. Sehn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
- (2021) Michael R. Bishop et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
- (2021) Frederick L. Locke et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma
- (2020) Tao Wang et al. Immunotherapy
- LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation
- (2019) Andrei Colita et al. Frontiers in Oncology
- High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party
- (2018) Stephen Paul Robinson et al. BONE MARROW TRANSPLANTATION
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- (2014) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur
- (2012) Christian H. Geisler et al. BRITISH JOURNAL OF HAEMATOLOGY
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
- (2010) B. Coiffier et al. BLOOD
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
- (2010) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now